News

Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...
Piper Sandler Lifts PT on Verona Pharma (VRNA) Stock, Maintains Overweight
Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Piper ...
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Merck to Buy Verona Pharma in $10 Billion Deal
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Verona Pharma Stock Jumps 20%. Why Merck Is Buying the Biotech.
Merck has reached an agreement to acquire British pharmaceutical company Verona Pharma in a deal worth around $10 billion, ...
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
Explore more
BioPharma Dive15h
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
These Stocks Are Moving the Most Today: Nvidia, AES, Verona Pharma, WPP, Bloom Energy, Aehr Test Systems, and More
Nvidia’s valuation crosses $4 trillion, while AES stock rises sharply following a report that says the renewable power ...
STAT2d
Merck to buy lung-disease biotech Verona Pharma for $10 billion
Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...
Raleigh pharma's $10B sale pays off for Boston, NY investment firms
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...